Molbio Diagnostics IPO Day 1 Subscription Reaches 0.34 Times as QIBs Lead Investor Demand
5paisa Capital Ltd
- 2 min read
Last Updated: 10th August 2026 - 04:29 pm
Molbio Diagnostics Limited's initial public offering (IPO) was subscribed 0.34 times by 5:24 PM on August 10, 2026. The public issue received bids for 27,37,620 shares against 81,58,529 shares available for subscription. The Qualified Institutional Buyers (QIBs) category led the demand with a subscription of 0.63 times, followed by the Employee (EMP) portion at 0.46 times, while the Non-Institutional Investors (NIIs) and Retail Individual Investors (RIIs) portions were subscribed 0.24 times and 0.21 times, respectively.
Invest in Indian Markets and Unlock Future Potential With 5paisa!Subscription Status of Molbio Diagnostics IPO
| Date | QIB | NII | Retail | EMP | Total |
|---|---|---|---|---|---|
| Day 1 (August 10) | 0.63 | 0.24 | 0.21 | 0.46 | 0.34 |
Here are the subscription details for Molbio Diagnostics IPO Day 2, as of 5:24 PM:
| Investor Category | Subscription (times) | Shares Offered | Shares bid for | Total |
|---|---|---|---|---|
| Anchor | 1 | 34,87,717 | 34,87,717 | 281.459 |
| QIB | 0.63 | 23,25,146 | 14,60,952 | 117.899 |
| NII | 0.24 | 17,43,859 | 4,15,764 | 33.552 |
| Retail | 0.21 | 40,69,004 | 8,51,364 | 343.641 |
| EMP | 0.46 | 20,520 | 9,540 | 0.770 |
| Total | 0.34 | 81,58,529 |
27,37,620 |
820.244 |
Key Highlights – Day 1
- Overall subscription stood at 0.34 times on Day 1 (August 10, 2026).
- Qualified Institutional Buyers (QIBs) subscribed 0.63 times.
- Non-Institutional Investors (NIIs) subscribed 0.24 times.
- Retail Investors subscribed 0.21 times.
- Employee (EMP) portion subscribed 0.46 times.
- Anchor investors had fully subscribed their allocated portion before the issue opened, with 34,87,717 shares allotted.
- Overall, the IPO was subscribed 0.34 times on the opening day.
About Molbio Diagnostics Limited
Incorporated in October 2000, Molbio Diagnostics Limited is a global point-of-care (POC) molecular diagnostics company engaged in the research, development, manufacturing, and commercialization of rapid diagnostic solutions for infectious and non-communicable diseases. The company has developed its proprietary 'Truenat' platform, a portable, battery-operated PCR-based molecular diagnostics system designed for resource-limited settings, offering accurate test results within an hour.
- FREE IPO Application
- Apply with Ease
- Pre-Apply for IPOs
- UPI Bid Instantly
Trending on 5paisa
5paisa Capital Ltd
Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.